Michael Yellin

Author PubWeight™ 31.38^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.	J Clin Oncol	2006	7.40
2	Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.	Clin Cancer Res	2007	5.51
3	Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.	Ann Surg Oncol	2005	5.36
4	Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.	J Clin Oncol	2004	4.09
5	Phase I/II study of ipilimumab for patients with metastatic melanoma.	J Clin Oncol	2008	2.79
6	Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.	Clin Cancer Res	2010	1.54
7	Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.	J Clin Oncol	2007	1.38
8	Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.	Curr Opin Investig Drugs	2005	1.34
9	Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.	Sci Transl Med	2014	1.30
10	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.	Gut	2013	1.05
11	Suppression of murine cardiac allograft arteriopathy by long-term blockade of CD40-CD154 interactions.	Circulation	2002	0.98